argenx SE ARGNF:OTCPK

*Data is delayed | Exchange | USD
Last | 03/21/24 EDT
383.74UNCH (UNCH)
52 week range
341.00 - 505.00
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close383.74
  • 52 Week High505.00
  • 52 Week High Date11/10/23
  • 52 Week Low341.00
  • 52 Week Low Date12/20/23

Key Stats

  • Market Cap21,286.07M
  • Shares Out59.19M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close383.74
  • 52 Week High505.00
  • 52 Week High Date11/10/23
  • 52 Week Low341.00
  • 52 Week Low Date12/20/23
  • Market Cap21,286.07M
  • Shares Out59.19M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-5.14
  • P/E (TTM)-74.66
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On argenx SE

 

Profile

MORE
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor...
Peter Verhaeghe
Non-Executive Independent Chairman of the Board
Tim Van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Karen Massey
Chief Operating Officer
Karl Gubitz
Chief Financial Officer
Malini Moorthy
General Counsel
Address
Laarderhoogtweg 25
Amsterdam
1101 EB
Netherlands